Stephen M Gottschalk
Overview
Explore the profile of Stephen M Gottschalk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa L, et al.
Cancer Immunol Res
. 2019 Jan;
7(3):363-375.
PMID: 30651290
Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive...
2.
Yanir A, Hanson I, Shearer W, Noroski L, Forbes L, Seeborg F, et al.
Biol Blood Marrow Transplant
. 2018 Apr;
24(8):1643-1650.
PMID: 29630926
There is a lack of consensus regarding the role and method of hematopoietic stem cell transplantation (HSCT) on patients with chronic granulomatous disease (CGD). Long-term follow-up after HSCT in these...
3.
Prinzing B, Gottschalk S, Krenciute G
Expert Rev Anticancer Ther
. 2018 Mar;
18(5):451-461.
PMID: 29533108
The outcome for patients with glioblastoma (GBM) remains poor, and there is an urgent need to develop novel therapeutic approaches. T cells genetically modified with chimeric antigen receptors (CARs) hold...
4.
Zhu S, Denman C, Cobanoglu Z, Kiany S, Lau C, Gottschalk S, et al.
Pharm Res
. 2013 Nov;
32(3):779-92.
PMID: 24203492
Purpose: Natural killer (NK) cell cytotoxicity correlates with the ligation of activating receptors (e.g., NKG2D) by their ligands (e.g., MHC class I-related chains [MIC] A and B) on target cells....
5.
Yu F, Wang X, Guo Z, Bartlett D, Gottschalk S, Song X
Mol Ther
. 2013 Oct;
22(1):102-11.
PMID: 24135899
Oncolytic vaccinia virus (VV) therapy has shown promise in preclinical models and in clinical studies. However, complete responses have rarely been observed. This lack of efficacy is most likely due...
6.
Gerdemann U, Katari U, Papadopoulou A, Keirnan J, Craddock J, Liu H, et al.
Mol Ther
. 2013 Jun;
21(11):2113-21.
PMID: 23783429
Adoptive transfer of virus-specific T cells can prevent and treat serious infections with Epstein-Barr virus (EBV), cytomegalovirus (CMV), and adenovirus (Adv) after allogeneic hematopoietic stem cell transplant. It has, however,...
7.
Gerdemann U, Keukens L, Keirnan J, Katari U, Nguyen C, de Pagter A, et al.
Blood
. 2012 Nov;
121(1):207-18.
PMID: 23152545
Human herpesvirus (HHV) 6 causes substantial morbidity and mortality in the immunocompromised host and has no approved therapy. Adoptive transfer of virus specific T cells has proven safe and apparently...
8.
Gerdemann U, Katari U, Christin A, Cruz C, Tripic T, Rousseau A, et al.
Mol Ther
. 2011 Sep;
19(12):2258-68.
PMID: 21915103
Although immunotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) can treat EBV-associated Hodgkin and non-Hodgkin lymphoma (HL/NHL), more than 50% of such tumors are EBV negative. We now describe...
9.
Nakazawa Y, Huye L, Salsman V, Leen A, Ahmed N, Rollins L, et al.
Mol Ther
. 2011 Jul;
19(12):2133-43.
PMID: 21772253
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) can be modified to function as heterologous tumor directed effector cells that survive longer in vivo than tumor directed T cells without virus...
10.
Lin Y, Lairson D, Chan W, Du X, Leung K, Kennedy-Nasser A, et al.
Biol Blood Marrow Transplant
. 2010 Mar;
16(9):1272-81.
PMID: 20348004
In a retrospective study, we evaluated the cost and cost-effectiveness of allogeneic peripheral blood stem cell transplantation (PBSCT) (n = 30) compared with bone marrow transplantation (BMT) (n = 110)...